Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT

Intersect ENT logoIntersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENT
  • CUSIP:
Key Metrics:
  • Previous Close: $12.85
  • 50 Day Moving Average: $12.98
  • 200 Day Moving Average: $13.61
  • 52-Week Range: $7.65 - $20.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.62
  • P/E Growth: 0.25
  • Market Cap: $367.05M
  • Outstanding Shares: 28,564,000
  • Beta: 0.82
Profitability:
  • Net Margins: -35.69%
  • Return on Equity: -21.25%
  • Return on Assets: -19.16%
Debt:
  • Current Ratio: 9.37%
  • Quick Ratio: 8.84%
Additional Links:
Companies Related to Intersect ENT:

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $19.80 (54.09% upside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017Canaccord GenuityReiterated RatingBuy$16.00View Rating Details
1/11/2017WedbushReiterated RatingOutperform$25.00View Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00View Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00View Rating Details
11/2/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$25.00 -> $16.00View Rating Details
10/18/2016Deutsche Bank AGSet Price TargetHold$17.00View Rating Details
8/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$21.00View Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00View Rating Details
3/29/2016Northland SecuritiesInitiated CoverageOutperform$26.00View Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00View Rating Details
12/18/2015Bank of America CorpInitiated CoverageBuy$26.00View Rating Details
10/2/2015Sterne Agee CRTReiterated RatingBuy$37.00View Rating Details
4/8/2015CRT CapitalInitiated CoverageBuy$32.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Intersect ENT (NASDAQ:XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.20)$23.47 millionN/AView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intersect ENT (NASDAQ:XENT)
Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.31)($0.14)($0.27)
Q2 20165($0.29)($0.12)($0.24)
Q3 20163($0.32)($0.25)($0.27)
Q4 20163($0.20)($0.15)($0.18)
Q1 20172($0.31)($0.21)($0.26)
Q2 20172($0.25)($0.19)($0.22)
Q3 20172($0.29)($0.13)($0.21)
Q4 20171($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 77.81%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intersect ENT (NASDAQ:XENT)
DateHeadline
News IconWhat are Analysts Expecting for Intersect ENT, Inc. (NASDAQ:XENT) Earnings? - Aiken Advocate (NASDAQ:XENT)
aikenadvocate.com - February 22 at 10:54 AM
prnewswire.com logoPurcell Julie & Lefkowitz LLP (NASDAQ:XENT)
www.prnewswire.com - February 21 at 4:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Intersect ENT, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:XENT)
finance.yahoo.com - February 21 at 4:17 PM
News IconIntersect ENT Inc XENT Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:XENT)
www.bioportfolio.com - February 18 at 11:12 AM
businesswire.com logoIntersect ENT to Report Fourth Quarter and Year 2016 Financial Results - Business Wire (press release) (NASDAQ:XENT)
www.businesswire.com - February 4 at 6:58 AM
finance.yahoo.com logoIntersect ENT to Report Fourth Quarter and Year 2016 Financial Results (NASDAQ:XENT)
finance.yahoo.com - February 4 at 6:58 AM
finance.yahoo.com logoIntersect ENT to Present at LEERINK Partners Global Healthcare Conference (NASDAQ:XENT)
finance.yahoo.com - February 2 at 6:55 AM
News IconWatching the Numbers for Intersect ENT, Inc. (NASDAQ:XENT) - Gilbert Daily (NASDAQ:XENT)
gilbertdaily.com - January 30 at 9:37 AM
News IconTrending Stocks Alert: WGL Holdings Inc. (NYSE:WGL), Intersect ENT, Inc. (NASDAQ:XENT) - The Newburgh Press (NASDAQ:XENT)
newburghpress.com - January 30 at 9:37 AM
News IconTrading Focus: Checking ATR Levels for Intersect Ent Inc. (XENT) - Sherwood Daily (NASDAQ:XENT)
sherwooddaily.com - January 29 at 6:41 AM
News IconRSI, CCI, and ADX Levels in View for Intersect Ent Inc. (XENT) - Market Point (NASDAQ:XENT)
mtptnews.com - January 27 at 6:53 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Intersect ENT, Inc. (NASDAQ:XENT) - Wall Street Beacon (NASDAQ:XENT)
wsbeacon.com - January 22 at 8:28 AM
4-traders.com logoINTERSECT ENT, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:XENT)
www.4-traders.com - January 21 at 5:46 AM
biz.yahoo.com logoINTERSECT ENT, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:XENT)
biz.yahoo.com - January 21 at 5:46 AM
News IconStock Tracker: Earnings & Estimates for Intersect ENT, Inc. (NASDAQ:XENT) - Aiken Advocate (NASDAQ:XENT)
aikenadvocate.com - January 18 at 5:55 AM
News IconWill The Needle Move For Intersect ENT, Inc. (NASDAQ:XENT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:XENT)
wsbeacon.com - January 18 at 5:55 AM
News IconInvestor Guide: Check on Technical Levels for Intersect Ent Inc. (XENT) - Springdale Times (NASDAQ:XENT)
springdaletimes.com - January 16 at 9:33 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Intersect ENT, Inc. (NASDAQ:XENT) - Wall Street Beacon (NASDAQ:XENT)
wsbeacon.com - January 15 at 5:21 AM
marketexclusive.com logoIntersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Regulation FD Disclosure (NASDAQ:XENT)
marketexclusive.com - January 10 at 4:24 PM
biz.yahoo.com logoINTERSECT ENT, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:XENT)
biz.yahoo.com - January 9 at 8:25 PM
finance.yahoo.com logoIntersect ENT Reports Preliminary Q4 and Year 2016 Revenue (NASDAQ:XENT)
finance.yahoo.com - January 9 at 3:23 PM
finance.yahoo.com logo8:05 am Intersect ENT issues Q4 prelim revenue guidance at $24.0-24.2 mln vs. $23.1 mln Capital IQ Consensus Est.; sees 1Q17 guidance at $19.0-19.5 mln vs. $19.5 mln consensus, sees 2017 revenue guidance at $87-89 mln vs. $87.7 mln consensu (NASDAQ:XENT)
finance.yahoo.com - January 9 at 3:23 PM
News IconAre There Catalysts to Propel This Stock Forward: Intersect ENT, Inc. (NASDAQ:XENT) - Prospect Journal (NASDAQ:XENT)
prospectjournal.com - January 2 at 8:12 PM
capitalcube.com logoIntersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : December 29, 2016 (NASDAQ:XENT)
www.capitalcube.com - December 30 at 3:40 AM
capitalcube.com logoIntersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : December 28, 2016 (NASDAQ:XENT)
www.capitalcube.com - December 28 at 8:01 AM
News IconReady for an Upsurge? Analysts Chime in on Intersect ENT, Inc. (NASDAQ:XENT) - Prospect Journal (NASDAQ:XENT)
prospectjournal.com - December 27 at 8:08 AM
businesswire.com logoIntersect ENT to Present at the 35th Annual J.P. Morgan Healthcare Conference - Business Wire (press release) (NASDAQ:XENT)
www.businesswire.com - December 21 at 9:25 PM
capitalcube.com logoETFs with exposure to Intersect ENT, Inc. : December 21, 2016 (NASDAQ:XENT)
www.capitalcube.com - December 21 at 4:24 PM
finance.yahoo.com logoIntersect ENT to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:XENT)
finance.yahoo.com - December 21 at 11:41 AM
News IconVC Score In Focus for Intersect ENT, Inc. (NASDAQ:XENT) - The Business Journal (NASDAQ:XENT)
belmontbusinessjournal.com - December 13 at 1:52 AM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Intersect ENT, Inc. (NASDAQ:XENT) - Prospect Journal (NASDAQ:XENT)
prospectjournal.com - December 13 at 1:52 AM
investornewswire.com logoCan Shares Of Intersect ENT, Inc. (NASDAQ:XENT) Hit $25? - Investor Newswire (NASDAQ:XENT)
www.investornewswire.com - December 11 at 7:35 PM
istreetwire.com logoStocks In Queue: LifeLock, Inc. (LOCK), Rockwell Collins, Inc. (COL), Intersect ENT, Inc. (XENT) - iStreetWire (NASDAQ:XENT)
istreetwire.com - December 10 at 9:31 AM
insidermonkey.com logoHere is What Hedge Funds Think About Intersect ENT Inc (XENT) (NASDAQ:XENT)
www.insidermonkey.com - December 8 at 10:11 AM
finance.yahoo.com logoCoverage initiated on Intersect ENT by Guggenheim (NASDAQ:XENT)
finance.yahoo.com - December 7 at 11:21 PM
investornewswire.com logoAnalyst Rating Of Intersect ENT, Inc. (NASDAQ:XENT) Revised To 1.5 - Investor Newswire (NASDAQ:XENT)
www.investornewswire.com - December 6 at 11:07 PM
News IconDirectional Index Update on Intersect Ent Inc. (XENT) - Yankee Analysts (NASDAQ:XENT)
yankeeanalysts.com - December 6 at 8:06 AM
capitalcube.com logoETFs with exposure to Intersect ENT, Inc. : December 5, 2016 (NASDAQ:XENT)
www.capitalcube.com - December 5 at 7:56 PM
News IconInvestor Watch on Shares of Intersect ENT, Inc. (NASDAQ:XENT) - Marion Business Daily (NASDAQ:XENT)
marionbusinessdaily.com - December 5 at 8:04 AM
News IconIntersect ENT Inc (NASDAQ:XENT) Investor News: Investigation over possible Violations of Securities Laws (NASDAQ:XENT)
www.groundreport.com - December 1 at 10:04 PM
News IconInvestor Hub: Checking on the Numbers for Intersect ENT, Inc. (NASDAQ:XENT) - Wall Street Lion (NASDAQ:XENT)
wslnews.com - November 25 at 8:07 PM
News IconIntersect ENT Inc. XENT Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:XENT)
www.bioportfolio.com - November 24 at 11:49 AM
investornewswire.com logoExpected For Intersect ENT, Inc. (NASDAQ:XENT) Sales Of $116.277 - Investor Newswire (NASDAQ:XENT)
www.investornewswire.com - November 23 at 8:40 PM
4-traders.com logoIntersect ENT : to Present at the Piper Jaffray 28th Annual Healthcare Conference (NASDAQ:XENT)
www.4-traders.com - November 22 at 8:39 PM
sbwire.com logoInvestigation for Investors in Shares of Intersect ENT Inc (NASDAQ:XENT) Announced (NASDAQ:XENT)
www.sbwire.com - November 22 at 8:39 PM
News IconFollowing FCF Scores for Intersect ENT, Inc. (NASDAQ:XENT) - Wall Street Lion (NASDAQ:XENT)
wslnews.com - November 22 at 1:18 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Intersect ENT, Inc. (NASDAQ:XENT) - CSZ News (NASDAQ:XENT)
cincysportszone.com - November 22 at 1:18 PM
News IconTechnical Monitor: Checking on Current Levels for Intersect Ent Inc. (XENT) - StockTalk Daily (NASDAQ:XENT)
stocktalkdaily.com - November 21 at 9:00 PM
News IconWhat The Charts Are Saying About Intersect ENT, Inc. (NASDAQ:XENT) - The Business Journal (NASDAQ:XENT)
belmontbusinessjournal.com - November 21 at 5:49 AM
News IconVolatility Check-in on Shares of Intersect ENT, Inc. (NASDAQ:XENT) - Wall Street Lion (NASDAQ:XENT)
wslnews.com - November 18 at 8:01 PM

Social

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 brokerages have issued 12 month target prices for Intersect ENT's shares. Their forecasts range from $14.00 to $29.00. On average, they expect Intersect ENT's stock price to reach $19.80 in the next twelve months.

When will Intersect ENT announce their earnings?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Federated Investors Inc. PA (4.60%), State Street Corp (1.61%), Kopp Investment Advisors LLC (1.25%), Thrivent Financial for Lutherans (1.05%), Royce & Associates LP (0.98%) and Allianz Asset Management AG (0.45%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Royce & Associates LP, Thrivent Financial for Lutherans and Allianz Asset Management AG. Company insiders that have sold Intersect ENT stock in the last year include Amy Wolbeck, Frederic H Moll, James Stambaugh, Lisa D Earnhardt and Richard E Kaufman.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Kopp Investment Advisors LLC, State Street Corp, Russell Investments Group Ltd., Denver Investment Advisors LLC, A.R.T. Advisors LLC, Flinton Capital Management LLC and Tyers Asset Management LLC.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intersect ENT stock cost?

One share of Intersect ENT stock can currently be purchased for approximately $12.85.

Intersect ENT (NASDAQ:XENT) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Earnings History Chart

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Dividend History Chart

Dividend Payments by Quarter for Intersect ENT (NASDAQ:XENT)

Last Updated on 2/23/2017 by MarketBeat.com Staff